Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Anti-diabetic and anti-obesity agent sodium tungstate enhances GCN pathway activation through Glc7p inhibition

  • Rodríguez Hernández, Carlos Javier
  • Guinovart, J.J.
  • Murguía, Jose R.|||0000-0001-9364-4603
[EN] Tungstate counteracts diabetes and obesity in animal models, but its molecular mechanisms remain elusive. Our Saccharomyces cerevisiae-based approach has found that tungstate alleviated the growth defect induced by nutrient stress and enhanced the activation of the GCN pathway. Tungstate relieved the sensitivity to starvation of a gcn2-507 yeast hypomorphic mutant, indicating that tungstate modulated the GCN pathway downstream of Gcn2p. Interestingly, tungstate inhibited Glc7p and PP1 phosphatase activity, both negative regulators of the GCN pathway in yeast and humans, respectively. Accordingly, overexpression of a dominant-negative Glc7p mutant in yeast mimicked tungstate effects. Therefore tungstate alleviates nutrient stress in yeast by in vivo inhibition of Glc7p. These data uncover a potential role for tungstate in the treatment of PP1 and GCN related diseases. (C) 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved., We thank R. Serrano for providing the Delta cnb1 mutant strain. We thank A. G. Hinnebusch for the gcn2-507 and gcn2 mutant strains. The pGEX-GLC7 plasmid was kindly provided by P. Sanz. The PP1-FLAG construct was kindly provided by A. C. Gingras. We thank T. Yates and J. Calbo for critical reading of the manuscript and helpful suggestions. J. J. Guinovart's laboratory was funded by grants from the Direccion General de Investigacion Cientifica y Tecnica (BFU2008-00769), the Generalitat de Catalunya (2009 SGR 01176), the Fundacion Marcelino Botin and the CIBER de Diabetes y Enfermedades Metabolicas Asociadas (ISCIII, Ministerio de Ciencia e Innovacion). J. R. Murguia laboratory was funded by Fondo de Investigaciones Sanitarias (FIS03-0628).
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

The differential effect of PGE1 on D-galactosamine-induced nitrosative stress and cell death in primary culture of human hepatocytes

  • Ranchal Illescas, Isidora
  • Gonzalez Ojeda, Raúl
  • López-Sánchez, Laura María
  • Barrera, Pilar
  • López-Cillero, Pedro
  • Serrano, Juan
  • Bernardos, Angel
  • De la Mata, Manuel
  • Rodríguez-Ariza, Antonio
  • Muntané Relat, Jordi
The pre-administration of PGE(1) reduced inducible nitric oxide synthase (NOS-2) expression and cell death induced by d-galactosamine (d-GalN) in cultured rat hepatocytes. The present study evaluated the role of nitric oxide (NO) during PGE(1) treatment in fully established d-GalN-induced cytotoxicity in cultured human hepatocytes. Human hepatocytes were isolated from liver resections by classic collagenase perfusion. PGE(1) (1 microM) was administered at 2 h before d-GalN (40 mM), or 2 or 10 h after d-GalN in cultured hepatocytes. The production of NO was inhibited by N-omega-nitroso-l-arginine methyl ester (l-NAME) (0.5 mM). Various parameters related to oxidative and nitrosative stress, mitochondrial dysfunction, NF-kappaB activation, NOS-2 expression and cell death were evaluated in hepatocytes. NO mediated mitochondrial disturbances, nitrosative stress and cell death in d-GalN-treated hepatocytes. The administration of PGE(1) 10 h after d-GalN enhanced NF-kappaB activation, NOS-2 expression and nitrosative stress. Although PGE(1) administered at 2 h before or 2h after d-GalN reduced apoptosis and necrosis, its administration 10 h after d-GalN had no beneficial effect on cell death. In conclusion, the administration of PGE(1) during advanced d-GalN cytotoxicity induced nitrosative stress and lost its cytoprotective properties in cultured human hepatocytes
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Serum osteoprotegerin in prevalent hemodialysis patients, associations with mortality, atherosclerosis and cardiac function

  • Collado, S.|||0000-0002-1812-1367
  • Coll, Elisabet|||0000-0003-0371-6250
  • Nicolau, Carlos|||0000-0002-1381-6442
  • Azqueta, Manel
  • Pons, Mercedes
  • Cruzado, Josep María
  • de la Torre, Bernat
  • Deulofeu, Ramón
  • Mojal, Sergi|||0000-0003-0523-3869
  • Pascual, Julio|||0000-0002-4735-7838
  • Cases Amenós, Aleix|||0000-0002-6962-8184
To assess whether serum osteoprotegerin (OPG) and/or fetuin-A predict mortality and cardiovascular (CV) morbidity and mortality in hemodialysis patients. Multicenter, observational, prospective study that included 220 hemodialysis patients followed up for up to 6 years. Serum OPG and fetuin-A levels were measured at baseline and their possible association with clinical characteristics, CV risk biomarkers, carotid ultrasonographic findings, as well as their association with overall and CV mortality and CV events were assessed. During a mean follow-up of 3.22 ± 1.91 years, there were 74 deaths (33.6%) and 86 new cardiovascular events. In the Kaplan-Meier survival analysis, the highest tertile of OPG levels was associated with higher overall mortality (p = 0.005), as well as a higher, although non-significant, incidence of CV events and CV mortality. In contrast, fetuin-A levels did not predict any of these events. OPG levels were directly associated with age, the Charlson comorbidity index (CCI), prevalent cardiovascular disease, carotid intima-media thickness, adiponectin, troponin-I and brain natriuretic peptide (BNP). OPG showed a negative correlation with left ventricular ejection fraction (LVEF) and phosphate levels. In the multivariate Cox proportional hazard analysis, all-cause mortality was associated with the highest tertile of OPG (HR:1.957, p = 0.018), age (HR:1.031, p = 0.036), smoking history (HR:2.122, p = 0.005), the CCI (HR:1.254, p = 0.004), troponin-I (HR:3.894, p = 0.042), IL-18 (HR:1.061, p < 0.001) and albumin levels (HR:0.886, p < 0.001). In the bootstrapping Cox regression analysis, the best cut-off value of OPG associated with mortality was 17.69 pmol/L (95%CI: 5.1-18.02). OPG, but not fetuin-A levels, are independently associated with overall mortality, as well as clinical and subclinical atherosclerosis and cardiac function, in prevalent hemodialysis patients. The online version of this article (10.1186/s12882-017-0701-8) contains supplementary material, which is available to authorized users.